Risk Management

2018 November Bulletin: Giant Cell Arteritis (based on 2015 GCA Claims Study)

November 2018 Risk Management Bulletin

Giant Cell Arteritis (GCA)

The short window for diagnosis and treatment and the risk of severe bilateral vision loss underscore the high stakes of this relatively rare condition.

Lawsuits for delay in diagnosis of GCA involve ophthalmologists who had treated patients with it, knew its signs and symptoms well, and understood that emergent treatment is needed to prevent imminent, bilateral vision loss. What, then, led these ophthalmologists astray?

Our resources explore the reasons for these poor outcomes, the standard to which medical experts hold physicians who treat these patients, and the measures ophthalmologists can take to improve the likelihood of a correct and timely diagnosis.


Giant cell arteritis claims are costly and difficult to defend

Giant Cell Arteritis Checklist

Please refer to OMIC's Copyright and Disclaimer regarding the contents on this website

Leave a comment

Six reasons OMIC is the best choice for ophthalmologists in America.

Consistent return of premium.

Publicly-traded insurance companies exist to make profits for shareholders while physician-owned carriers often return profits to their policyholders. Don’t underestimate this benefit; it can add up to tens of thousands of dollars over the course of your career. OMIC has one of the most generous dividend programs for ophthalmologists and has returned more than $90 Million to our members through dividends.